News | July 01, 2008

MMV forms Alliance with Accuray for CyberKnife Technology

July 2, 2008 - Montecito Medical Ventures (MMV) formed an alliance by purchasing two placement contracts from medical technology company Accuray, manufacturers of the CyberKnife radiosurgery system, creating a program that gives healthcare providers that are affiliated with Montecito Medical access to medical technologies through its financing program.

MMV will make a pool of investment capital for healthcare transactions available to providers interested in acquiring CyberKnife or other advanced medical technologies.

The CyberKnife Robotic Radiosurgery System is reportedly the world's only radiosurgery system that can treat tumors anywhere in the body with sub-millimeter accuracy. Using image guidance technology and computer controlled robotics, the CyberKnife System is designed to continuously track the tumor, detect its location and automatically make needed adjustments throughout the procedure. Because it is so precise, the CyberKnife system enables surgeons to be less invasive in their surgical procedures, and allows them to target tumors in any part of the body, including the head, neck, spine, lung, prostate, liver and pancreas. CyberKnife also provides an additional option for patients diagnosed with tumors believed to be inoperable, or for patients looking for an alternative to surgery.

MMV was launched in October 2007 to provide venture capital and partnership opportunities to physician groups in key markets across the country. A joint venture of the California-based Montecito Medical Investment Company, MMV targets resources where it has determined there is a need for expanded medical services, and where it has identified strong partners that have medical products or technologies that will benefit healthcare providers affiliated with MMIC. Capital investments will be targeted to real estate acquisition and development, and structured finance in medical technology.

For more information: www.accuray.com, www.montecitomedical.com

Related Content

University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
Accuray Radixact

Accuray Radixact

Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis
While radiation therapy as a disciplin
Sponsored Content | Case Study | Radiation Therapy | May 29, 2019
The so-called “Grey Tsunami” of baby boomers using healthcare services isn’t taking the Radiation Medicine Program at
Improved Imaging for Prostate Cancer Could Lead to More Effective Treatment

The picture shows that time series signal is extracted from a series of ultrasound frames for classification. Each patch across a number of frames inside the prostate is classified into either cancerous or normal tissue. The image at the lower right corner shows the overall result for those frames. Image courtesy of Pingkun Yan and researchers from NIH, University of British Columbia and Queens University.

News | Ultrasound Imaging | May 28, 2019
Engineers at Rensselaer Polytechnic Institute are working to improve imaging methods in order to make medicine more...
Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res